1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Benzodiazepine Receptor Agonist -Pipeline Insights, 2016

Benzodiazepine Receptor Agonist -Pipeline Insights, 2016

  • November 2016
  • -
  • Delve Insight
  • -
  • 60 pages


DelveInsight’s, “Benzodiazepine Receptor Agonist-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the Benzodiazepine Receptor Agonist. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Benzodiazepine Receptor Agonist. DelveInsight’s Report also assesses the Benzodiazepine Receptor Agonist therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope
- The report provides competitive pipeline landscape of Benzodiazepine Receptor Agonist
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Benzodiazepine Receptor Agonist pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Benzodiazepine Receptor Agonist and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

Benzodiazepine Receptor Agonist -Pipeline Insights, 2016

- Benzodiazepine Receptor Agonist Overview
- Benzodiazepine Receptor Agonist Disease Associated
- Benzodiazepine Receptor Agonist Pipeline Therapeutics
- Benzodiazepine Receptor Agonist Therapeutics under Development by Companies
- Benzodiazepine Receptor Agonist Filed and Phase III Products
- Comparative Analysis
- Benzodiazepine Receptor Agonist Phase II Products
- Comparative Analysis
- Benzodiazepine Receptor Agonist Phase I and IND Filed Products
- Comparative Analysis
- Benzodiazepine Receptor Agonist Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Benzodiazepine Receptor Agonist - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Benzodiazepine Receptor Agonist - Discontinued Products
- Benzodiazepine Receptor Agonist - Dormant Products
- Companies Involved in Therapeutics Development for Benzodiazepine Receptor Agonist
- Appendix
- Methodology
- Contact Us
- Disclaimer


List of Tables

- Number of Products under Development for Benzodiazepine Receptor Agonist by Therapy Area, 2016
- Number of Products under Development for Benzodiazepine Receptor Agonist, 2016
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2016
- Comparative Analysis Phase II Products, 2016
- Comparative Analysis Phase I and IND Filed Products, 2016
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2016
- Drug Candidates Profiles
- Benzodiazepine Receptor Agonist Assessment by Monotherapy Products
- Benzodiazepine Receptor Agonist Assessment by Combination Products
- Benzodiazepine Receptor Agonist Assessment by Route of Administration
- Benzodiazepine Receptor Agonist Assessment by Stage and Route of Administration
- Benzodiazepine Receptor Agonist Assessment by Molecule Type
- Benzodiazepine Receptor Agonist Assessment by Stage and Molecule Type
- Benzodiazepine Receptor Agonist Therapeutics - Discontinued Products
- Benzodiazepine Receptor Agonist Therapeutics - Dormant Products
- Products under Development by Companies, 2016

List of Figures

- Number of Products under Development for Benzodiazepine Receptor Agonist by Therapy Area, 2016
- Number of Products under Development for Benzodiazepine Receptor Agonist, 2016
- Filed and Phase III Products, 2016
- Phase II Products, 2016
- Phase I and IND Filed Products, 2016
- Discovery and Pre-Clinical Stage Products, 2016
- Benzodiazepine Receptor Agonist Assessment by Monotherapy Products
- Benzodiazepine Receptor Agonist Assessment by Combination Products
- Benzodiazepine Receptor Agonist Assessment by Route of Administration
- Benzodiazepine Receptor Agonist Assessment by Stage and Route of Administration
- Benzodiazepine Receptor Agonist Assessment by Molecule Type
- Benzodiazepine Receptor Agonist Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Sufentanil Citrate Market: By Applications (Surgery, Epidural Anaesthesia and Medicinal Application) & By Geography (North America, Europe, Asia Pacific & Rest of the World (RoW))-Forecast (2016-2021)

Sufentanil Citrate Market: By Applications (Surgery, Epidural Anaesthesia and Medicinal Application) & By Geography (North America, Europe, Asia Pacific & Rest of the World (RoW))-Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Sufentanil, also known as R30730 or brand name Sufenta, is a synthetic opioid analgesic drug which is considerably more potent than its parent drug, fentanyl, morphine. It is used for producing anesthesia ...

Global General Anesthesia Drugs Market - Growth, Trends, and Forecasts (2016 - 2021)

Global General Anesthesia Drugs Market - Growth, Trends, and Forecasts (2016 - 2021)

  • $ 4250
  • Industry report
  • October 2016
  • by Mordor Intelligence LLP

The global general anesthesia drugs market accounted for USD 3,840 million in 2015 and USD 3,983 million in 2016. The market is expected to reach USD 4,760 million by 2021, growing at a CAGR of 3.6% during ...

Global Local Anesthesia Drugs Market - Growth, Trends, and Forecasts (2016 - 2021)

Global Local Anesthesia Drugs Market - Growth, Trends, and Forecasts (2016 - 2021)

  • $ 4250
  • Industry report
  • October 2016
  • by Mordor Intelligence LLP

The global local anesthesia drugs market accounted for USD 8,160 million in 2015 and USD 8,335 million in 2016. The market is expected to reach USD 9,240 million by 2021, growing at a CAGR of 2.1% during ...


Download Unlimited Documents from Trusted Public Sources

Opioid and Anesthetics Market in Australia

  • December 2016
    5 pages
  • Opioid  

    Anesthetics  

    Analgesic  

  • Australia  

View report >

Opioid Market in the US

  • November 2016
    4 pages
  • Opioid  

  • United States  

View report >

Hormone Market in the US

  • November 2016
    20 pages
  • Hormone  

  • United States  

View report >

Related Market Segments :

Anesthetics

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.